All In MedTech

Device Trial Radar · NCT02155608

Trigeminal Nerve Stimulation for ADHD

Developmental Pilot Study of External Trigeminal Nerve Stimulation for ADHD

Last checked: Nov 19, 2026Latest source record: Jul 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

62

Actual

Start

Apr 1, 2015

Primary completion

May 30, 2018

Study completion May 30, 2018

Sponsor

Lead sponsor
University of California, Los AngelesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Mental Health (NIMH)
First posted
Jun 4, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 8 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to develop external Trigeminal Nerve Stimulation (eTNS) as a potential nonmedication treatment for attention-deficit/hyperactivity disorder (ADHD). Study hypothesis address potential differences over 4 weeks of active vs. sham eTNS treatment on ADHD symptoms, measures of executive function, electroencephalography (EEG) profiles, other dimensional measures of height, weight, mood, anxiety, and sleep, and side effect profiles.

Conditions

  • Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

  • Active eTNSDevice

    Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.

  • Sham eTNSDevice

    Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ADHD-IV Rating Scale (ADHD-RS)Time frame: Change over baseline and weeks 1, 2, 3, 4 and 5.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCLA Semel Institute

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.